Eli Lilly & Co. (LLY)

Oncology Corporate Profile

Stock Performance


HQ Location

Lilly Corporate Center
Indianapolis, IN 46285

Company Description

Eli Lilly is a leading innovation-driven pharmaceutical corporation that is developing a growing portfolio of pharmaceutical products. Lilly's products treat cancer, depression, schizophrenia, attention-deficit hyperactivity disorder, diabetes, osteoporosis and many other conditions.

Website: http://www.lilly.com

Brand Generic Indication
Alimta®pemetrexedAlimta® is a folate analog metabolic inhibitor indicated for:
Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer:
Initial treatment in combination with cisplatin. Maintenance treatment of patients whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. After prior chemotherapy as a single-agent. Mesothelioma: in combination with cisplatin. Alimta® is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.
Cyramza®ramucirumabCyramza® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated for the treatment of Gastric Cancer. Specifically, advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single - agent after prior fluoropyrimidine - or platinum - containing chemotherapy. Approved in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy to treat metastatic colorectal cancer (mCRC).
Erbitux®cetuximabErbitux® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:

Head and Neck Cancer
• Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.

• Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with 5-FU.

• Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.

Colorectal Cancer: K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer as determined by FDA-approved tests

• in combination with FOLFIRI for first-line treatment

• in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy,

• as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.

Limitation of Use: Erbitux® (cetuximab) is not indicated for treatment of K-Ras mutation-positive colorectal cancer.
Gemzar®gemcitabine hydrochlorideGemzar® in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

Gemzar® in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.

Gemzar® is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer.

Gemzar® is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemzar is indicated for patients previously treated with 5-FU.
Lartruvo®olaratumabLartruvo® is a platelet-derived growth factor receptor alpha (PDGFR) blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Lartruvo®olaratumabLartruvo® is a platelet-derived growth factor receptor alpha (PDGFR-_) blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Portrazza®necitumumabPortrazza® is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non - small cell lung cancer.
Verzenio™ (+ fulvestrant)abemaciclib (+ fulvestrant)Verzenio™ (+ fulvestrant) is a kinase inhibitor indicated:
-in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
-as monotherapy for the treatment of adult patients with HRpositive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ramucirumab / LY3009806VEGF receptor2nd line Bladder cancerIII
ramucirumab / LY3009806VEGF receptorGastric cancerIII
ramucirumab / LY3009806VEGF receptorHepatocellular carcinoma (HCC)III
ramucirumab / LY3009806VEGF receptorNon Small Cell Lung Cancer (NSCLC)III
ramucirumab / LY3009806VEGF receptorUrothelial cancerIII
Verzenio™ / abemaciclib / LY2835219CDK 4/6 inhibitorBreast cancerIII
Verzenio™ / abemaciclib (+ fulvestrant) / LY2835219CDK 4/6 inhibitorBreast cancerIII
Verzenio™ / abemaciclib / LY2835219CDK 4/6 inhibitorNon Small Cell Lung Cancer (NSCLC)III
galunisertib / LY2157299kinase inhibitorHepatocellular carcinoma (HCC)II
LY3023414PI3 Kinase/mTOR dual InhibitorNon Small Cell Lung Cancer (NSCLC)II
emibetuzumab / LY2875358c-Met inhibitorNon Small Cell Lung Cancer (NSCLC)II
ralimetinib / LY2228820 dimesylatep38 MAP kinase inhibitorOvarian cancerII
LY3023414PI3 Kinase/mTOR dual InhibitorProstate cancerII
prexasertib / LY2606368 monomesylate monohydrateCHK1 inibitorVarious cancer typesII
merestinib / LY2801653c-Met inhibitorVarious cancer typesII
LY3039478notch inhibitorVarious cancer typesII
LY2874455FGF receptor inhibitorVarious cancer typesII
LY2510924CXCR4 peptide inhibitorVarious cancer typesII
Verzenio™ / abemaciclib / LY2835219CDK 4/6 inhibitorSquamous Non Small Cell Lung Cancer (NSCLC)II
FGFR3-ADCantibody drug conjugates (ADC)Various cancer typesI
PD-L1monoclonal antibodyVarious cancer typesI
TGF® RIkinase inhibitorVarious cancer typesI
CHK1 inibitorCHK1 inibitorVarious cancer typesI
ERK inhibitorERK inhibitorVarious cancer typesI
CSF-1Rmonoclonal antibodyVarious cancer typesI
Angiopoietin 2monoclonal antibodyVarious cancer typesI

View additional information on product candidates here »

Source: http://www.lilly.com

Recent News Headlines

Exelixis Announces Presentation of Cobimetinib Combination Therapy Data at the Society for Melanoma Research 2016 Congress That Support Genentech’s Planned Phase 3 Pivotal Trials

11/7/2016 12:56 pm

(Yahoo! Finance) Nov 7, 2016 - Encouraging data in BRAF wild type advanced melanoma presented in advance of initiation of phase 3 pivotal trial next year; the third pivotal phase 3 trial of cobimetinib announced this year, reflecting robust late-stage development program.

Four Things Health Execs Should Know About the Oncology Pipeline

11/3/2016 04:44 pm

(Managed Healthcare Executive) Nov 3, 2016 - Oncology therapeutic and supportive care agents in the development pipeline promise to be more effective, more therapeutically targeted, more personalized—and far more costly, according to industry experts.

ASCO Updates Guidelines On Integration Of Palliative Care

11/3/2016 04:33 pm

(Doctors Lounge/HealthDay News) Nov 2, 2016 - The American Society of Clinical Oncology Clinical Practice Guideline on the integration of palliative care into standard oncology care has been updated. The update was published online Oct. 28 in the Journal of Clinical Oncology.

Palliative Care Should Be Standard In Cancer Treatment: Guideline

11/3/2016 11:53 am

(Reuters Health) Nov 2, 2016 – For patients with advanced cancer, palliative care should start early and be an integral part of treatment, not just something added on near the end of life, according to a new practice guideline from the American Society for Clinical Oncology (ASCO).

Doctors Spar Over Passing a California Proposition On Drug Price Relief

11/2/2016 04:36 pm

(CNBC) Nov 1, 2016 - Two doctors clashed Tuesday afternoon over their stances on California's Proposition 61, a referendum that would require state agencies to get the same discount on drugs as the Department of Veteran Affairs.

Association of Community Cancer Centers Releases White Paper on Challenges and Opportunities for Delivery of Patient-Centered Care

11/2/2016 04:29 pm

(ACCC) Nov 2, 2016 - Effective delivery of patient-centered care is essential to meet the Institute for Healthcare Improvement (IHI) Triple Aim – improved patient experience, improved outcomes, and reduced costs. As the U.S. healthcare system shifts from volume to value-based reimbursement, many new payment models incorporate patient satisfaction and/or patient experience measures when determining overall compensation.

ASCO Outlines the FDA’s Recent Regulation of Electronic Nicotine Delivery Systems and Tobacco Products in New Policy Brief

10/31/2016 03:38 pm

(ASCO in Action) Oct 27, 2016 - ASCO’s policy brief outlining the Food and Drug Administration’s (FDA) regulation of electronic cigarettes (e-cigarettes) and other Electronic Nicotine Delivery Systems (ENDS) was published in the Journal of Oncology Practice.

Adaptive Biotechnologies Announces the Inclusion of NGS-Based MRD Assessment in the NCCN Clinical Practice Guidelines for Multiple Myeloma

10/28/2016 05:19 pm

(Yahoo! Finance) Oct 27, 2016 - Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces that the National Comprehensive Cancer Network (NCCN) revised their clinical practice guidelines recommending the use of highly sensitive diagnostic tools, including NGS, to assess the presence of measurable residual disease (MRD) in Multiple Myeloma.

Bristol Hikes 2016 Profit Forecast as Top Drugs Deliver, Shares Jump

10/27/2016 04:45 pm

(Reuters) Oct 27, 2016 - Bristol-Myers Squibb Co, whose shares have plunged since its new Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after surprisingly strong quarterly sales of other leading medicines.

Myriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation's Largest Network of Community Oncologists

10/21/2016 05:16 pm

(Myriad) Oct 21, 2016 - Myriad Genetics, Inc., a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the support of community oncology, announced today that they have entered into a relationship to deliver quality hereditary cancer test results and services to ION member practices.

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early

10/21/2016 12:04 pm

(Merck) Oct 21, 2016 - Merck, known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).

FACT SHEET: Vice President Biden Delivers Cancer Moonshot Report, Announces Public and Private Sector Actions to Advance Cancer Moonshot Goals

10/17/2016 04:11 pm

(WhiteHouse.gov/Office of the Vice President) Oct 17, 2016 - Today in the Oval Office, Vice President Joe Biden delivered the Cancer Moonshot report to the President and the American public.

HHS Issues Final Rule to Enhance the Reliability, Transparency, Accountability, and Safety of Certified Health Information Technology

10/14/2016 04:34 pm

(HHS.gov) Oct 14, 2016 - Today, the U.S. Department of Health and Human Services’ (HHS) Office of the National Coordinator for Health Information Technology (ONC) issued a final rule that emphasizes the importance of protecting public health and safety while also strengthening transparency and accountability in the ONC Health IT Certification Program (“Program”).

ASCO Issues New Guideline for Global Cervical Cancer Screening

10/13/2016 04:07 pm

(Medscape Medical News) Oct 12, 2016 - A new global guideline on screening for cervical cancer, which provides evidence-based recommendations for screening, follow-up, and treatment for high-risk lesions, has been released by the American Society of Clinical Oncology (ASCO).

New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)

10/12/2016 04:09 pm

(Sirtex) Oct 11, 2016 - Sirtex Medical Limited announced today that the European Society of Medical Oncology (ESMO) has indicated the use of SIRT using yttrium-90 (Y-90) microspheres as an option for the treatment of intrahepatic cholangiocarcinoma (iCCA), a form of primary liver cancer that starts in the bile duct, the branching network of thin tubes that deliver fat-digesting bile from the liver to the small intestine.

Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

10/11/2016 06:06 pm

(Yahoo! Finance) Oct 11, 2016 - CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration.

New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients

10/10/2016 02:49 pm

(Merck) Oct 8, 2016 - Results from interim analysis of phase 2 KEYNOTE-052 study to be presented at ESMO 2016 Congress and highlighted in ESMO press program; first presentation of data investigating KEYTRUDA in the front line treatment of bladder cancer.

Exelixis and Pfizer Drugs Compete In Kidney Cancer Trial

10/10/2016 02:46 pm

(Reuters) Oct 10, 2016 - Exelixis's drug Cabometyx outperformed Pfizer's Sutent in a clinical study for the treatment of metastatic kidney cancer, suggesting it has the potential to become a first-line treatment, researchers said on Monday.

UTSW Researchers Find Use of PSA for Prostate Screening Unaffected by Changes in Screening Guidelines

10/7/2016 04:06 pm

(UT Southwestern Medical Center) Oct 6, 2016 - Controversy over prostate cancer screening guidelines that discourage use of PSA tests did not significantly reduce use of the test, a five-year review of more than 275,000 visits at UT Southwestern Medical Center showed.

Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress

10/7/2016 04:00 pm

(Yahoo! Finance) Oct 7, 2016 - Seattle Genetics, Inc. and Agensys, an affiliate of Astellas, today presented updated clinical data for enfortumab vedotin (ASG-22ME) and ASG-15ME at the European Society for Medical Oncology (ESMO) Congress being held October 7-11, 2016 in Copenhagen, Denmark.

Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors

10/7/2016 03:59 pm

(Yahoo! Finance) Oct 7, 2016 - Exelixis, Inc. today announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors.

Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress

10/7/2016 03:58 pm

(Yahoo! Finance) Oct 7, 2016 - Exelixis, Inc. today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the triple combination of cobimetinib, vemurafenib, and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma.

PharmaMar Shows New Clinical Data on Yondelis® and Lurbinectedin at ESMO 2016

10/5/2016 04:08 pm

(PharmaMar) Oct 5, 2016 - Results of an oral presentation will highlight the Phase II clinical trial results with lurbinectedin in patients with BRCA 1/2 metastatic breast cancer; a prospective randomized phase III comparing trabectedin versus the best supportive care in patients with pretreated advanced soft tissue sarcoma (T- SAR trial) will be presented in an oral session by the French Sarcoma Group.

Need to Revisit Cervical Cancer Screening Guidelines: JAMA Oncology Study

9/30/2016 04:44 pm

(AJMC) Sept 29, 2016 - Untreated human papillomavirus (HPV) infection has been identified as a leading cause of developing cervical intraepithelial neoplasia (CIN), which can lead to invasive cervical cancer. While several studies have documented the success of HPV vaccination in preventing the viral infection and development of low-grade and high-grade CIN, the impact of subsequent reduced screening rates have not been examined.

‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors

9/30/2016 04:35 pm

(UCSF) Sept 29, 2016 - UC San Francisco scientists have engineered human immune cells that can precisely locate diseased cells anywhere in the body and execute a wide range of customizable responses, including the delivery of drugs or other therapeutic payloads directly to tumors or other unhealthy tissues.

FDA Approves ERBITUX(R) (cetuximab) as First-Line Treatment in KRAS Mutation-Negative (Wild-Type) Epidermal Growth Factor Receptor (EGFR)-Expressing Metastatic Colorectal Cancer in Combination with FOLFIRI (Irinotecan, 5-Fluorouracil, Leuco

7/6/2012 11:00 pm

[Business Wire] - Eli Lilly and Company and Bristol-Myers Squibb Company today announced that ERBITUX® in combination with the chemotherapy regimen FOLFIRI has been granted full approval by the U.S.

Strengthening the Portfolio

7/6/2012 04:03 pm

Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta® (duloxetine HCl)

7/6/2012 12:00 pm

[PR Newswire] - INDIANAPOLIS, July 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has met the United States Food and Drug Administration (FDA) requirements for pediatric exclusivity ...

Commerce Department Keeps Icann as Web’s Address Manager

7/3/2012 04:05 pm

[at Bloomberg] - Commerce Department Keeps Icann as Web's Address Manager